Mike Bonney


Mike Bonney is business executive with over 30 years of biotech and pharmaceutical expertise. Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating, and strategic roles, ending his career there as National Business Director.

Bonney chairs the boards of Alnylam Pharmaceuticals, Kaleido Biosciences and Magenta Therapeutics.  He is a member of several other boards, including Bristol Myers Squibb. Bonney spends much of his time identifying and mentoring the next generation of life science leaders.

Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). He received his undergraduate degree in economics from Bates College.

Mike and his family have a wide range of philanthropic interests including education – Mike chaired the Board of Bates College from 2010 – 2019; the Gulf of Maine Research Institute, where the Bonney’s focus is on sustainable economic activity in the rapidly changing Gulf of Maine, with a specific focus on shellfish and seaweed aquaculture; and Rare, an international NGO focused on inspiring change, so people and nature thrive.